APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
Aptevo Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.60−0.02 (-1.23%)
Close on Oct 19, 2026
- Market cap
- $1.91M
- P/E (TTM)
- –
- Dividend yield
- –
Aptevo Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Aptevo Therapeutics | Industry median |
|---|---|---|
| Market Cap | $2.88M | $166.30M |
| Enterprise Value | -$6.91M | $87.12M |
| PB Ratio | 0.48 | 2.03 |
| P/TBV Ratio | 0.48 | 2.31 |
Income (trailing twelve months)
| Measure | Aptevo Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$26.89M | -$21.49M |
| Net Income | -$26.41M | -$22.46M |
| EBITDA | -$26.69M | -$17.14M |
Returns
| Measure | Aptevo Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -420.3% | -53.2% |
| Return on Assets (ROA) | -175.2% | -41.0% |
| Return on Capital Employed (ROCE) | -288.1% | -38.0% |
Balance sheet
| Measure | Aptevo Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $9.80M | $62.64M |
| Net Cash (Debt) | $9.80M | $15.77M |
| Net Cash Per Share | $5.44 | $0.66 |
| Equity (Book Value) | $6.04M | $48.61M |
| Book Value Per Share | $3.35 | $1.36 |
| Tangible Book Value | $6.04M | $23.01M |
| Working Capital | $5.61M | $75.09M |
Financial position
| Measure | Aptevo Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 2.08 | 3.30 |
| Quick Ratio | 1.89 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Aptevo Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$25.34M | -$12.39M |
Efficiency
| Measure | Aptevo Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$660.20K | -$705.27K |
| Employee Count | 40 | 74 |
Dividends and yields
| Measure | Aptevo Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -915.9% | -22.8% |
| Buyback Yield | -873.1% | -0.73% |
| Shareholder Yield | -873.1% | 0.00% |
Shares
| Measure | Aptevo Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 1,801,970 | 58,139,000 |
| Shares Change (QoQ) | 17.9% | 0.54% |
| Float | 1,544,410 | 49,154,900 |
| Shares Held by Insiders | 14.3% | 11.6% |
| Shares Held by Institutions | 2.80% | 59.4% |
Scores
| Measure | Aptevo Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -33.24 | -0.27 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Aptevo Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.